Premium
How Epigallocatechin‐3‐gallate and Tetracycline Interact with the Josephin Domain of Ataxin‐3 and Alter Its Aggregation Mode
Author(s) -
Bonanomi Marcella,
Visentin Cristina,
Natalello Antonino,
Spinelli Michela,
Vai Marco,
Airoldi Cristina,
Regonesi Maria E.,
Tortora Paolo
Publication year - 2015
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201503086
Subject(s) - epigallocatechin gallate , chemistry , gallate , domain (mathematical analysis) , biophysics , mode (computer interface) , tetracycline , computer science , biochemistry , polyphenol , biology , mathematics , nuclear chemistry , human–computer interaction , antioxidant , mathematical analysis , antibiotics
Abstract Epigallocatechin‐3‐gallate (EGCG) and tetracycline are two known inhibitors of amyloid aggregation able to counteract the fibrillation of most of the proteins involved in neurodegenerative diseases. We have recently investigated their effect on ataxin‐3 (AT3), the polyglutamine‐containing protein responsible for spinocerebellar ataxia type 3. We previously showed that EGCG and tetracycline can contrast the aggregation process and toxicity of expanded AT3, although by different mechanisms. Here, we have performed further experiments by using the sole Josephin domain (JD) to further elucidate the mechanism of action of the two compounds. By protein solubility assays and FTIR spectroscopy we have first observed that EGCG and tetracycline affect the JD aggregation essentially in the same way displayed when acting on the full‐length expanded AT3. Then, by saturation transfer difference (STD) NMR experiments, we have shown that EGCG binds both the monomeric and the oligomeric JD form, whereas tetracycline can only interact with the oligomeric one. Surface plasmon resonance (SPR) analysis has confirmed the capability of the sole EGCG to bind monomeric JD, although with a K D value suggestive for a non‐specific interaction. Our investigations provide new details on the JD interaction with EGCG and tetracycline, which could explain the different mechanisms by which the two compounds reduce the toxicity of AT3.